Podcasts about wegovy

Plus: Andreessen Horowitz raises over $15 billion across several funds. And LG Electronics expects to post a quarterly operating loss for the first time since 2016. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, Jim Cramer and David Faber led off the show with market reaction to the December employment report: Non-farm jobs growth came in lower than expected, up 50,000. The unemployment rate fell to 4.4%. National Economic Council Director Kevin Hassett joined the program with White House reaction to the results. The anchors and Hassett discussed him being in the running for Fed chair, the Supreme Court's upcoming decision on tariffs and what to expect from President Trump's Friday meeting with oil CEOs about reviving production in Venezuela. Also in focus: The stocks surging on Meta's nuclear deals, Amazon's pharmacy to offer Novo Nordisk's Wegovy pill.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

January 8, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Trump administration releases new dietary guidelines backed by HHS Secretary RFK Jr., recommending avoidance of ultra-processed foods and added sugars while endorsing red meat and full-fat dairy Eli Health unveils instant saliva-based tests for testosterone and progesterone at $8 per test, with results in minutes and Q1 rollout ahead Mark Mastrov and LongRange Capital reacquire 24 Hour Fitness, with plans to upgrade clubs for strength and recovery while preparing for international growth Smart ring shipments jumped 50% in 2025, outpacing smartwatches as Oura explores digital IDs and payments beyond health tracking Novo Nordisk's Wegovy pill launches nationwide as first oral GLP-1 for weight loss at $149/month through pharmacies and telehealth providers More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

Studies show that more you spend on your wedding, the more likely you are to get a divorce. Fred and the crew discuss! And Wegovy users are having a hard time keeping weight off after they stop using... Listen now!See omnystudio.com/listener for privacy information.

Studies suggest that once you stop taking wegovy, you could gain the weight you lost back. Open AI is launching Chat GPT Health. New US dietary guidelines change the alcohol guidelines.See omnystudio.com/listener for privacy information.

Seattle is desperately trying to backtrack after reports it was moving towards drug decriminalization. Just like Minnesota, Washington is dealing with its own allegations of fraud. There’s now a pill version of the popular weight loss drug Wegovy. // LongForm: GUEST: Let's Go Washington's Brian Heywood on what's next now that two citizen intitiatives have received enough signatures to make it on the ballot. // Quick Hit: An update on allegations that Hilton hotels were denying reservations to ICE agents.

(January 07, 2025) A report by U-Haul shows California recorded the largest exodus of do-it-yourself movers of any state in 2025. KFI reporter Heather Brooker joins the show from a neighborhood in Altadena where the rebuilding has started. Dr. Jim Keany, Chief Medical Officer at Dignity Health St. Mary Medical Center in Long Beach, joins The Bill Handel Show for 'Medical News'! Dr. Keany talks with Bill about the CDC slashing vaccine recommendations for kids, flu reaching the highest levels in the U.S. in 25 years, and Wegovy now in pill form.See omnystudio.com/listener for privacy information.

For the full episode, search 'Quite right!' wherever you are listening now. This week: Michael and Maddie dissect Donald Trump's audacious raid on Venezuela and ask what it reveals about power, national interest and the unravelling of the rules-based order. Was America acting like a rogue state – or simply doing what states do when their interests are at stake? And could Britain learn a thing or two from how they conduct their foreign policy, specifically with regard to the Chagos Islands?Then, closer to home, they unpack the scandal surrounding West Midlands Police and the banning of Maccabi Tel Aviv fans. Who really made the call – and what does it tell us about two-tier policing and the erosion of equal justice?And finally: are weight-loss jabs like Ozempic and Wegovy quietly reshaping society – and what will happen when the prices drop later this year?Produced by Oscar Edmondson.To submit your urgent questions to Michael and Maddie, visit spectator.co.uk/quiteright Hosted on Acast. See acast.com/privacy for more information.

 President Trump rallies the House GOP as midterms ratchet up, minimum wage hikes up in several states, and Wegovy ditches the needle. Get the facts first with Evening Wire. - - - Ep. 2566 - - - Wake up with new Morning Wire merch: https://bit.ly/4lIubt3 - - - Privacy Policy: https://www.dailywire.com/privacy morning wire,morning wire podcast,the morning wire podcast,Georgia Howe,John Bickley,daily wire podcast,podcast,news podcast Learn more about your ad choices. Visit podcastchoices.com/adchoices

This episode opens the year with one of the most consequential—and complicated—weeks in GLP-1 obesity medicine. We break down three stories that, taken together, reveal why patients are increasingly reading past headlines and demanding accountability from the industry. First, we examine early-phase trial data from Arrowhead Pharmaceuticals, after headlines claimed its experimental INHBE-targeting therapy “nearly doubled” the weight loss of Zepbound. We walk through what the data actually showed, why the comparison was misleading, how trial design and dosing matter, and why Phase 1 results should never be treated as superiority claims. Next, we turn to a major access milestone: the official launch of oral Wegovy, the first FDA-approved GLP-1 pill for obesity from Novo Nordisk. We discuss how this pill differs from compounded oral semaglutide, why its pricing strategy is so disruptive, and what this launch means for people who have avoided injectable medications. We also explore how direct-to-consumer access, telehealth partnerships, and retail pharmacy distribution signal a broader shift in how obesity care is being delivered. Finally, we address the most ironic—and uncomfortable—story of the week: manufacturing quality concerns involving branded Wegovy pens, reported to include biological particulate matter, at the same time Novo Nordisk continues a years-long public and legal campaign against compounded GLP-1 medications on safety grounds. We discuss FDA inspection history, the acquisition of Catalent, and why credibility depends on consistency—especially when millions of patients are paying close attention. This episode isn't anti-pharma or pharma-friendly. It's patient-first. And it asks a simple question: Who do we trust when science, marketing, access, and manufacturing all collide at once? Episode Timestamps 00:00 — Why this first episode of 2026 matters 02:10 — Hair found in Wegovy pens and why patients notice hypocrisy 06:15 — Arrowhead trial headlines vs. what the data actually shows 11:40 — Why tirzepatide dosing and trial design matter 17:30 — What INHBE targeting may actually be good for (and what it's not) 21:45 — Sponsor: SHED and access pathways for obesity care 25:10 — Oral Wegovy officially launches: what's different this time 30:20 — How the Wegovy pill works and why bioavailability matters 35:40 — Pricing, telehealth, Costco, and direct-to-consumer access 41:50 — Why pills lower barriers for millions of patients 46:10 — Manufacturing quality, Catalent, and FDA citations 52:30 — Why safety arguments against compounding are being scrutinized 58:40 — Zooming out: access, accountability, and patient trust 1:02:00 — Final thoughts and what to watch next Topics Covered GLP-1 trial hype vs. real-world context Phase 1 data limitations and headline inflation Tirzepatide dosing and misleading comparisons Oral Wegovy vs. compounded oral semaglutide GLP-1 pill pricing and insurance implications Direct-to-consumer pharma and telehealth disruption Manufacturing quality and FDA oversight Compounding pharmacies and healthcare system resilience Patient trust, transparency, and credibility in obesity medicine Useful Links & Resources On The Pen Links & Advocacy: https://otplinks.com Sponsor – SHED (use code OTP25): https://tryshed.com FDA Drug Safety & Recalls: https://www.fda.gov/drugs Follow On The Pen: YouTube: https://youtube.com/@onthepen Substack: https://onthepen.substack.com Support the Show If this episode helped you better understand what's really happening in obesity medicine: Leave a 5-star rating and review Hit Subscribe so you don't miss future episodes Join us live Mondays, Wednesdays, and Fridays at 12pm Eastern on YouTube Patients deserve clarity. That's what we're here for. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Look at that! It's January 6th! Today also happens to be "National Take Down Your Xmas Tree Day", and we discussed why it always falls on 1/6. In the news this morning, the latest on the US taking control of Greenland, the Wegovy pill is now available, a Wisconsin supper club closes after a fire, and Charlie Hunnam's wife wasn't too happy with his Ed Gein voice at home. In sports, a bunch of coaches got fired on Black Monday, the Badger men's basketball plays tonight, the Bucks play tomorrow night, the NBA is going to play more preseason games in China next year, and the Brewers made some coaching moves recently. We let you know what's on TV today/tonight and what's new on New Release Tuesday. Also, a list of TV shows that are turning 50 in 2026. Grant Bilse from the Wisco Sports Show joined us just after 8am to talk about the upcoming NFL playoffs and his visit with Brian on Sunday. Some inspirational stories this morning about a woman who crashed into a bayou in Houston but got saved by a guy in a boat, an animal rescuer who donated thousands of boxes of pet supplies, and another successful year for the Hershey Bears teddy-bear toss. As the final week of the NFL regular season wrapped up on Sunday, it was time to check in on our Week 18 Pigskin Picks and sort out when Jean will be making that seafood paella for Brian. And in today's edition of "Bad News with Happy Music", we had stories about a woman who ran over her boyfriend in a Taco Bell parking lot, a #FloridaMan who tried to run over a kid on a scooter because he thought the kid was a porch pirate, a #FloridaTeen who got popped for doing 154mph, and a dude in Scotland who took a full-on kick to the balls!See omnystudio.com/listener for privacy information.

US to ‘run' Venezuela after Maduro taken into custody: Trump; Wegovy pill becomes available to consumers; Napheesa Collier talks injury, season 2 of 'Unrivaled' Learn more about your ad choices. Visit podcastchoices.com/adchoices

Wegovy's first weight-loss pill is now available nationwide. Also, experts predict 2026 health trends will focus on expanded GLP-1 use, AI-powered wearable devices, and the “food as medicine” approach. Plus, author Adam Grant discusses how to unlock your hidden potential for greater success. And, NBC turns 100 in 2026, celebrating a century of news, entertainment, and memories. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

US to ‘run' Venezuela after Maduro taken into custody: Trump; Wegovy pill becomes available to consumers; Napheesa Collier talks injury, season 2 of 'Unrivaled' Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. Weight loss medications are evolving at lightning speed. But once you start digging online, it's easy to feel unsure about what's real, what's safe, and what your options actually are if a medication stops working.In this episode, I walk you through what's genuinely on the horizon between 2026–2028, using the clinical data we have right now. We're talking higher-dose oral Wegovy, more affordable non-refrigerated options, and the triple agonist many people are waiting for, with nearly 29% average weight loss. Tune in to find out how these medications work, what the research is showing so far, and why this pipeline offers real hope for anyone managing obesity as a chronic disease.ReferencesTimeline of upcoming obesity medicationsColoring recommendations:Alcohol Markers Coloring books Season 2 of The Obesity Guide: Behind the Curtain PodcastGet my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey.Audio Stamps00:30 – The importance of building a dopamine menu with non-food hobbies to manage obesity long-term.06:08 – Staying open to new treatments and pivoting strategies in managing a chronic, lifelong disease.07:48 – Oral Wegovy coming early 2026 with improved results and affordability.10:00 – Higher-dose Wegovy subq arriving with 21% average weight loss.11:50 – Orforglipron: a new non-refrigerated oral GLP-1 option.12:40 – CagriSema combines semaglutide with amylin for enhanced results.14:20 – Retatrutide overview and warnings about unregulated versions.15:All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show

In this episode, Gianna Beasley welcomes listeners to 2026 and discusses the importance of setting health goals for the new year. She outlines a roadmap for success on a GLP-1 journey, emphasizing the need for reflection, refocusing, consistency, and celebrating progress. The conversation is structured around four phases that guide listeners through their health journey, encouraging self-awareness and sustainable habits.

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored and reported by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Market update for Monday January 5, 2026Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode:U.S. oil stocks rally as investors bet on long-term upside in VenezuelaNovo Nordisk launches the first-ever GLP-1 weight-loss pill in the U.S.Mobileye jumps after landing a major U.S. automaker for self-driving techComcast slides as its cable spinoff Versant officially begins tradingCES kicks off in Vegas as tech giants test consumer demand for AI hardware

The US will "run" Venezuela until a "safe, proper and judicious transition" can be ensured, Donald Trump has said, after US strikes led to the capture of the Latin American country's president and his rendition to New York.What happens next in Venezuela? There's been celebration and condemnation of America's intervention. We'll hear from in Caracas and also the Colombia-Venezuela border.Also in the programme: We also hear from a former Trump insider who worked with him on Venezuela, ask a leading international criminal lawyer about the legality of the situation; and we'll hear about weight-loss drugs such as Ozempic, Mounjaro and Wegovy.(Photo shows Venezuela's President Nicolas Maduro at the offices of the U.S. Drug Enforcement Administration (DEA) in New York. Credit: White House's Rapid Response 47 account on X.com)

Happy Holidays from Frequency Podcast Network! This week we'll be joined by the Friends of Frequency (FOF).In this special feed drop on The Big Story, Host Alex Seixeiro speaks to Abbey Sharp, registered dietician and host of the Bite Back podcast, to discuss all the diet trends of 2025. They dig into the dos and don'ts of diet culture, and which habits we you should leave behind heading into 2026. We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstoryfpn on Twitter

Today, we're diving into an exciting development in obesity treatment—oral semaglutide.  Last week, the FDA approved Novo Nordisk's Wegovy pill as the first and only oral GLP-1 for weight loss in adults. This approval is based on results from the OASIS-4 phase 3 clinical trial showing that a once-daily oral version of semaglutide can deliver nearly the same weight loss results as the injectable form.  So, what does that really mean for patients and treatment options? Let's break it down. Read the Full Episode Transcript: https://pepties.com/oral-semaglutide/ Dr. Nikki's Qualifications: https://bifat.life/about/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ BioLongevity Labs (Purchase Peptides online) Use our link and enter COUPON CODE: PEPTIDEPODCAST at checkout to receive 15% off your total order https://go.biolongevitylabs.com/aff_c?offer_id=1&aff_id=1582&aff_sub=PEPTIDEPODCAST Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

On today's Good Day Health Show - ON DEMAND…Dr. Jack Stockwell, a NUCCA Chiropractor and GAPS Practitioner in SLC, UT (866.867.5070 | ForbiddenDoctor.com | JackStockwell.com), covers the the biggest news in the health and wellness space from a holistic, naturopath perspective. In this episode, Dr. Jack covers a common question he gets about estrogens, specifically for women who are under the treatment of cancer (mainly breast cancer). Dr. Jack advices against any external source of estrogen for women going through breast cancer treatment. Unfortunately, it's not as simple as avoiding certain supplements. A lot of beef, lamb, especially poultry, are increasingly contaminated with artificial estrogens which have been injected into the animals in order to fatten them up and/or increase their rate of growth to get to the market faster. All the more reason to avoid commercial-farming and support local farmers which you can see how their animals are raised and the quality in place. Continuing on, Dr. Jack explains why we are the sickest and the most overweight country on the planet, and why the food choices are a primary culprit. Most other countries have real food in their grocery stores. Here in the US, we have an abundance of food-like products. Much of our processed foods contain chemicals and ingredients that have been banned in other countries, often from the same brand. Why would brands create two types of the same food with one being of better quality for other countries with stricter guidelines vs what is permitted and sold here. Then, the health conversation shifts to healthy weight with Doug's conversation with Elizabeth Miller from Calotren to talk about the New Year and the common resolution for weight loss and overall health. The best way to approach the New Year isn't as simple as having goals, but having a sustainable plan to go with those goals. With a stronger focus on healthy bodies, many have turned to weight loss injectables like Ozempic and Wegovy, but along with the weigh loss comes loss of muscle mass and other issues. With Calotren, you can take only that for your weight loss journey, or you can add Calotren to the injectables routine because it helps to rebuild the lean muscle tissue, tone and repair. While the injectables aren't sustainable for long term use, Calotren is. Learn more on toploss.com or give them a call to speak directly with one of their coaches at 833-TOPLOSS (833-867-5677).Plus, there is a free gift card with every order of Calotren right now to go towards future orders. Don't forget to use the code “DOUG” at checkout for free shipping. Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

Looking at a weird GDP data point. Calling BS on Russia/Ukraine peace talks. Gold and Silver – WOW! Closing out the year – a good one too! PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - CTP Cup - All systems go! 9 participants! - Lots to be excited about and anxious too - Looking at a weird GDP data point - Calling BS on Russia/Ukraine peace talks Markets - Gold and Silver - WOW! - Closing out the year - a good one too! - Buyers are still hot to buy any dip - "Diet" pills coming Bitters Making Progress  - Chocolate -Dark Cherry -Infusions - https://highdesertbotanicals.com NYE Celebration - Cities across America ring in the new year by dropping unexpected objects: - Amelia Island, FL drops a giant shrimp. - Nashville drops a 400lb musical note with 28,140 LEDs. - Boise, ID, drops a glowing potato. - Key West, FL, drops an eight-foot ruby-red heel—complete with a drag queen inside! - In Spain, revelers gulp down 12 grapes—one for each midnight chime—to bring luck for each month - Denmark - Danes toss old dishes at friends' doors—large piles of broken crockery at dawn are seen as tokens of good luck. What a year! - So many themes in 12 months - AI, Tariffs, War and Trade War, Fat drugs, Deglobalization - Data centers, semiconductors, and supporting infrastructure like power and cooling systems. - Approx: DJIA +13.5%, SP500 +17%, NASDA +21%, BTCUSD -7.6%, Gold +64%, SLV +145%, $DXY -9.5%, EEM +30% - 2026 - Opportunities and Auld Lang Xiety (Tech still looks frothy in certain names) Top New Year's Resolutions - Exercise More - Eat Healthier - Save More Money/Get Out of Debt - Be Happy/Improve Mental Health - Lose Weight - Spend More Time with Family & Friends - Learn a New Skill/Hobby - Get Organized Active Management (Funds) - Same report annually - A small group of tech super stocks accounted for an outsize share of returns in 2025, extending a pattern in place for the better part of a decade. - Around $1 trillion was pulled from active equity mutual funds over the year, marking an 11th year of net outflows, while passive equity exchange-traded funds got more than $600 billion. - The concentration of gains in a few stocks made it harder for active managers to do well, with 73% of equity mutual funds trailing their benchmarks this year, the fourth most in data going back to 2007. - BUT, there are some areas that it makes sense for active management ---- Equity vs Fixed income and reasoning --- Efficient markets, boots on the ground Fat Pill - The FDA has approved the first-ever GLP-1 pill from Wegovy maker Novo Nordisk. - Novo Nordisk said the starting dose of 1.5 milligrams will be available in early January in pharmacies and via select telehealth providers with savings offers for $149 per month. - The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill. - Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January PowerBall - A ticket sold in Arkansas scored a $1.8 billion Powerball jackpot after Wednesday night's draw — one of the richest lottery prizes in U.S. history, landing just in time for Christmas. - The payout soared after last Monday's drawing produced no winners, with last-minute ticket sales pushing the jackpot to $1.817 billion. That makes it the second-largest U.S. lottery prize ever and the biggest Powerball of 2025, the lottery website said on Thursday. - The winning numbers — 4, 25, 31, 52, 59 and the Powerball 19 - Odds: one in 292.2 million. Silver - Amazing year! - Sunday night futures - >$83 then turned hard lower| - Down 7% on Monday - Range $83 - $71 (15%) for the day - Some rumors about a bank collapse due to wrong way position on Silver - forced liquidation and covering.... ----- Hard to believe that a bank was short that much silver - but..... SoKo Breach - South Korean online retail giant Coupang said it will offer 1.69 trillion South Korean won ($1.17 billion) in compensation to 34 million users affected by a massive data breach disclosed last month. - That is about 4% of Coupang's annual revenue - but a big chunk of their profit - $34 per user NVDA Deal - Nvidia has yet to issue a public announcement or disclosure regarding its $20 billion Groq deal that CNBC was first to cover on Wednesday. - Groq described the deal as a “non-exclusive licensing agreement,” a tool that's been used by tech giants of late in part to avoid regulatory scrutiny. - Analyst: “Antitrust would seem to be the primary risk here, though structuring the deal as a non-exclusive license may keep the fiction of competition alive,” Bernstein's Stacy Rasgon wrote in a report. - Groq will remain an independent company (?) GDP Consumption - Something is a bit off.... - With the marketplace costs increasing, this may be more than a one-off expenditure Q3 GDP Surge Russia/Ukraine - Less that an hour after the White House claimed great movement toward peace - Russian President Putin told President Trump that Russia will revise its negotiating position, raising questions over prospects for peace deal - Russian Foreign Minister Sergei Lavrov says Ukraine tried to attack Russian President Putin's residence - Does anyone even listen to the crap coming out of the White House anymore? - Did you hear Lutnick trying to explain the 600% reduction in costs for pharmaceuticals? Math wizards! - - For 2026, my wish is that they continue to work on the job at hand and just shut up Just for fun - Who is biggest drinker of spirits? - While there's no single official "heaviest drinker," legendary wrestler Andre the Giant is widely cited as having unmatched capacity, famously downing 119 beers in one sitting (or even up to 156 in other accounts) Oil - Crude oil futures down about 9.5% YTD - Much of the drop due to pick up in production (supply/demand) - Still a floor with as Russia, Nigeria, Venezuela etc - What will it take to move up? Best Auto Stock for 2025? - GM! Better than ford, Tesla and others (up 55%) - best year from coming out of bankruptcy in 2009 - Ford up 35% - Mary Barra, CEO selling into the strength - $73 M sold this year (Position down 73% from what she held last year) - - - Barra has contended for years that stock undervalued. With all of these say what does that say now? --- Would she ever say shares are overvalued? More fun stats - A peer?reviewed 2025 study estimates AI data centers (including indirect usage from electricity generation) consumed 312–765 billion liters of water annually. That's more than all bottled water consumed worldwide each year - Direct (on-site) water is used for cooling servers via systems like cooling towers or liquid loops. Indirect (off-site) water stems from electricity generation—particularly from thermal and nuclear plants, which require significant cooling resources - ??? Estimates suggest a single standard AI prompt (about 100 words) is linked to around 1.5 liters of water—accounting for the entire chain of consumption. (This is total usage from cooling powr consumption, electricity generation) - Global AI workloads consumed 50–60 terawatt-hours (TWh) in 2025—roughly the annual electricity use of a medium-sized country like Switzerland. - By 2030, AI-related electricity demand could reach 300–500 TWh annually, according to energy analysts—comparable to the entire electricity consumption of countries like France. Over to Iran - President Trump tells reporters that if Iran is building up its nuclear program, the U.S. will have to "knock them down" again --- Wait - I thought we destroyed all of their nuke aspirations??? - - - AND - Iran's currency hit a record low, triggering wave of protests, according to Bloomberg Fed News - Top Fed Chair Candidate Odds Narrow Again, With Hassett at 43% and Warsh at 35% - President Trump still angry at Powell 0threating to sue for incompetence Odd - Tesla Inc. published a series of sales estimates indicating the outlook for its vehicle deliveries may be lower than many investors were expecting. - The carmaker posted estimates showing analysts on average expect the company to deliver 422,850 cars in the fourth quarter, down 15% from a year earlier. - Tesla is on course for its second consecutive drop in annual vehicle sales, with the company compiling an average estimate for 1.6 million deliveries, down more than 8% from a year earlier. - These are estimates published by analysts - Tesla put on its own site - WHY? End of Year Stat - The U.S. national debt is climbing at a rapid pace and has shown no signs of slowing down despite the growing criticism of massive levels of government spending. - The national debt, which measures what the U.S. owes its creditors, rose to $38,386,384,190,622.68 as of Dec. 30, according to the latest numbers published by the Treasury Department. - That is an increase of about $5.8 billion daily - ~$18 per person in the US per day increase ($7,300) - or about the monthly price of leasing a small Mercedes - Each person in US owes approx $128,000 Love the Show? Then how about a Donation? THE CLOSEST TO THE PIN 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Participants: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

In this episode, we examine the realities behind universal health care by looking at Canada's system, wait times, medical tourism, and cases where patients are denied life-saving treatment. We discuss the rise of weight-loss drugs like Ozempic and Wegovy, the economics behind high drug prices, and why “miracle” medications often create new dependencies and unintended costs. We scrutinize airline incivility, declining standards of behavior, and why airlines are reluctant to enforce norms despite growing problems. Phil Magness also joins us to discuss the internal collapse of the Heritage Foundation, the rise of post-liberal conservatism, and the growing influence of figures like Tucker Carlson and Nick Fuentes. We explore tensions within the Republican Party, the appeal of emergency powers on both the left and right, the dangers of mixing religion with state authority, and what these trends mean for the future of American politics. 00:00 Introduction and Overview 00:28 Canadian Health Care and the Myth of “Free” Medicine 02:38 When Universal Health Care Denies Life-Saving Treatment 04:50 Wait Times, Medical Tourism, and U.S. vs Canada Outcomes 06:16 Ozempic, Wegovy, and the Economics of Weight-Loss Drugs 08:52 Why Expensive Drugs Create Cheaper Alternatives 10:05 Side Effects, Dependency, and the Cost of “Miracle” Drugs 10:36 Airline Incivility and Delta's Class-Based Explanation 12:28 Why Airlines Refuse to Enforce Behavioral Standards 13:52 Why Flying Is Cheaper Than Ever (and Why That Matters) 15:22 Horror Stories From the Skies 18:07 Introducing Phil Magness 19:14 The Implosion of the Heritage Foundation 22:34 Tucker Carlson, Nick Fuentes, and the Post-Liberal Right 25:24 Mass Resignations and the Collapse of Heritage's Core 28:52 Post-Liberalism and the Rejection of the American Founding 32:00 Is the Republican Party Fracturing? 34:34 Mike Pence and the Future of Free-Market Conservatism 37:08 The Left and Right's Shared Authoritarian Instincts 39:21 Emergency Powers, Carl Schmitt, and Executive Absolutism 44:06 Why Emergency Government Always Expands 46:58 Christian Nationalism and Catholic Integralism 50:03 Why Religion and State Power Don't Mix 52:12 Who Really Wants Political Power? 54:52 Trump as a Lame-Duck President 55:45 JD Vance, 2028, and Electoral Reality 58:11 Why Both Parties Keep Nominating Losers 01:02:27 Conclusion Learn more about your ad choices. Visit podcastchoices.com/adchoices

En el Radar Empresarial de esta jornada ponemos el foco en el negocio de los medicamentos para perder peso en Asia, un mercado que ha despertado un fuerte interés entre las grandes farmacéuticas. Novo Nordisk y Eli Lilly han identificado a China como un territorio clave para su expansión y ya han comenzado a mover ficha. Ambas compañías han decidido reducir de forma significativa el precio de sus tratamientos adelgazantes en el país con vistas al próximo año. En el caso de la empresa danesa, el coste de Wegovy se ha recortado casi a la mitad, mientras que la multinacional estadounidense ha lanzado Mounjaro por 445 yuanes, muy por debajo de los más de 2.000 que costaba antes. Los cambios en los hábitos sociales han convertido a China en un mercado enorme, impulsado por el crecimiento de la clase media y una dieta cada vez más calórica. Este contexto ha provocado un aumento sostenido del sobrepeso y la obesidad. Las estimaciones apuntan a que en 2030 más del 65% de la población china podría sufrir alguno de estos problemas. Ante este escenario, también han surgido iniciativas locales para desarrollar fármacos propios, como Mazdutide, una inyección creada por Innovent Biologics junto a Eli Lilly China, con pérdidas de peso cercanas al 15% tras 48 semanas. El desafío sanitario no se limita a Asia y también es prioritario en Estados Unidos, donde la obesidad y la diabetes ocupan un lugar central en la agenda pública. China, de hecho, es el país con más personas con diabetes: en 2024 se contabilizaban 148 millones de adultos, según la International Diabetes Federation. Por ello, firmas globales y competidores locales compiten por el liderazgo, mientras Novo Nordisk y Eli Lilly refuerzan sus vínculos con las autoridades chinas e impulsan nuevas inversiones estratégicas. Este acercamiento busca asegurar presencia a largo plazo y apoyar los objetivos del plan China Saludable 2030 oficial nacional.

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest on Ozempic from medical breakthroughs to lifestyle shifts.Ozempic, a glucagon-like peptide one receptor agonist, mimics a hormone to boost insulin, slow stomach emptying, curb appetite, and quiet food noise. The American Cancer Society notes it was first approved for type two diabetes but now aids weight loss with diet and exercise, delivering average losses of fifteen to twenty percent of body weight in studies.Recent research from the University of Texas at Arlington highlights up to twenty percent body weight reduction over months through appetite suppression. Yet, AOL reports real-world data shows an average five point one percent loss on semaglutides like Ozempic.Exciting medical news: A Danish and Canadian trial in CU Anschutz Medicine found obese knee osteoarthritis patients on weekly GLP-one agonists had major pain relief and better function. Orthopedics expert Karin Payne sees huge promise for these drugs in easing arthritis symptoms by cutting weight.Psychology Today's December twenty ninth, twenty twenty five study reveals Ozempic reshapes more than bodies. Users feel normal and happier post-loss but face emotional hits from past stigma. Demand surges from weight anxiety, even in slim nations like Japan, fueled by social media. Many endure nausea, fatigue, and costs, tweaking doses via TikTok tips, blurring into disordered eating risks.The New York Times reports older adults over sixty five quit GLP-one drugs like semaglutide within a year at sixty percent rates, regaining weight and facing muscle loss that hurts fitness. Shortages contributed.Big update: Reuters says the Food and Drug Administration just approved Novo Nordisk's twenty five milligram oral semaglutide pill as Wegovy for obesity or overweight with conditions, expanding access beyond injections.Cancer links remain mixed per the American Cancer Society: possible lower risks for breast, prostate, and others, but avoid if thyroid cancer history.Pair Ozempic with healthy eating, exercise, and doctor guidance for best results.Thanks for tuning in, listeners. Subscribe for more updates. This has been a Quiet Please production. For more, check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

If society privileges "thin" people, should you aspire to conform? And at what cost?Last year, online influencer Slim Kim went viral for a TikTok where she said she loves "being skinny." It sparked a debate that continued throughout 2025: how do we talk about bodies without falling into "body fascism." And with drugs like Ozempic and Wegovy flooding the market, how are the ways we talk about bodies shifting and changing?Brittany is joined by authors Emma Specter and Kate Manne to find out: what's so wrong with loving being skinny?This episode originally aired on December 6, 2024.Support Public Media. Join NPR Plus.Follow Brittany Luse on Instagram: @bmluseFor handpicked podcast recommendations every week, subscribe to NPR's Pod Club newsletter at npr.org/podclub.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

12-29-25 - Study On Wegovy And Other Similar Weight Loss Drugs Finds It's Enhancing Users Sexual Appetite - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Best You Podcast, Nick sits down with Dr. Will Bulsiewicz—New York Times bestselling author, award-winning gastroenterologist, founder of 38TERA, and one of the world's leading voices in gut health. Dr. B is passionate about helping people understand the foundational role their gut plays in both everyday health and long-term disease prevention.We dive deep into the microbiome, the gut lining, the immune system, and how they're all connected. Dr. B explains how conditions like constipation, bloating, diarrhea, IBS, and more are often rooted in gut dysfunction—and most importantly, what to do about it.From how much fiber you should eat daily to how GLP-1s (like Ozempic and Wegovy) are affecting your gut, this conversation is packed with cutting-edge insight and practical takeaways.What You'll Learn:●      What your gut microbiome is and why it matters for your entire body●      How your gut lining affects immunity, inflammation, and long-term health●      How many different plants to eat each week for optimal microbiome diversity●      How much fiber Dr. B recommends daily (and why most of us fall short)●      How GLP-1 drugs are impacting digestion and gut health●      First steps to take if you're dealing with constipation, diarrhea, IBS, or general gut dysfunction

Feeling stuck? If your GLP-1 weight loss has slowed down or stopped, you're not alone and it does not mean the medication stopped working. In this episode, Gianna walks you step-by-step through her checklist for stalls, which she uses to help GLP-1 clients restart progress without panic, restriction, or jumping doses.Listen to learn how to fuel properly, protect your metabolism, check your consistency, and adjust habits so your results return- calmly and confidently. ✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

12-29-25 - Study On Wegovy And Other Similar Weight Loss Drugs Finds It's Enhancing Users Sexual Appetite - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a message with this link, we would love to hear from you. Standard message rates may apply. Oral Wegovy is officially FDA approved — but what does that actually mean for patients? In this episode of Your Checkup, we break down the December 2025 approval of oral semaglutide 25 mg for chronic weight management, who qualifies, how it works, and how effective it really is. We review the clinical trial data behind the approval, including expected weight loss, common side effects, and long-term expectations, and explain how oral Wegovy compares to injectable GLP-1 medications. We also tackle common misconceptions, dosing and lifestyle considerations, and the very real challenges of cost and insurance coverage. If you've heard the headlines and want the facts — without hype — this episode is for you. Check out our new graphics. Thank you, Vantage Design Works. Check out our website, you can send us an email, yourcheckuppod@gmail.com. Check out our website, you can find us on Instagram, share us with a friend or a neighbor. But most importantly, stay healthy, my friends.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN Artwork Rebrand and Avatars: Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/ Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr Original Artwork Concept: Olivia Pawlowski

  In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: The 10 Best Breakfast Foods for Lean Gains. (2:52) Elon is playing chess. (18:36) A homerun protein snack. (26:07) This new machine has Sal excited. (28:06) If you can be a collector of anything, what would that be? (30:33) When old styles become the new thing again. (37:45) Hack for parents with teenagers who are getting into strength training. (41:00) How much exercise do you need to KEEP the muscle you've already built? (46:38) Body contouring with red-light therapy. (49:38) It's about people, not money. (55:21) #ListenerCoaching call #1 – How to overcome constant muscle fatigue. (57:57) #ListenerCoaching call #2 – How to determine the next fitness focus after making significant progress. (1:07:35) #ListenerCoaching call #3 – Advice regarding daily protein intake without shakes and scaling unilateral exercises while following MAPS Split. (1:17:02) #ListenerCoaching call #4 – Advice and tips you may have for navigating my new endeavor of opening a small boutique personal training studio. (1:28:59) Related Links/Products Mentioned Get Coached by Mind Pump, live! Visit https://www.mplivecaller.com  Visit Crisp Power for an exclusive offer for Mind Pump listeners! ** Code MINDPUMP10 for 20% off. Give your snack game a serious upgrade. Crisp Power Protein Pretzels deliver super crunchy and delicious snacks that are up to 28g of protein, low carb, zero sugar, and high in fiber! ** Visit Joovv for an exclusive offer for Mind Pump listeners! ** Code MINDPUMP to get $50 off your first purchase. 0% financing available! ** MAPS 15 Powerlift 50% half from Dec. 21-27th. Code DECEMBER50 at checkout. Mind Pump Store SpaceX Will IPO in 2026. How Much Is SpaceX Stock Worth? Maintaining Physical Performance: The Minimal Dose of Exercise Needed to Preserve Endurance and Strength Over Time Effects of Red Light LED Therapy on Body Contouring HOME | Stoik Gym Visit Paleovalley for an exclusive offer for Mind Pump listeners! ** Discount is now automatically applied at checkout 15% off your first order! ** Mind Pump #2450: The Smartest Way to Use Protein to Burn Fat & Build Muscle Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Online Personal Training Course | Mind Pump Fitness Coaching ** Approved provider by NASM/AFAA (1.9 CEUs)! Grow your business and succeed in 2025. ** Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Dr. Stephen Cabral (@stephencabral) Instagram Jeremy L. Buendia (@jeremy_buendia) Instagram  

Headlines: – Welcome To Mo News (02:00) – AAA Expecting A Record-Setting Year For Holiday Travel (04:30) – Record-Breaking Warmth Chases Away White Christmas Dreams (06:00) – Justice Department Releases New Batch Of Documents In Epstein Investigation (07:00) – U.S. Economic Growth Surged in Third Quarter of 2025 (14:15) – FDA Approves New Wegovy Weight Loss Pill (16:20) – Supreme Court Refuses to Allow National Guard Deployment in Chicago (18:20) – How to Track Santa Claus This Christmas Eve With NORAD's 2025 Tracker (20:30) – What We're Watching, Reading, Eating (23:30) Thanks To Our Sponsors:  – LMNT⁠ - Free Sample Pack with any LMNT drink mix purchase –⁠ Industrious⁠ - Coworking office. 50% off day pass | Promo Code: MONEWS50 – Incogni - 60% off an annual plan| Promo Code: MONEWS – Aura Frames -  $35 off best-selling Carver Mat frames | Promo Code: MONEWS – Monarch - 50% off your first year | Promo Code: MONEWS

In this episode of the Smarter Not Harder Podcast, Cynthia Thurlow joins Dr. Scott Sherr for a wide-ranging and refreshingly honest conversation about fasting, female hormones, GLP-1s, and navigating midlife as a high-performing woman. With clarity and nuance, Cynthia breaks down what works — and what backfires — when it comes to metabolic health for women over 35. Join us as we delve into: • Why intermittent fasting isn't a one-size-fits-all solution • How hormone shifts change the fasting game for women • What GLP-1s like Ozempic and Wegovy really do — and don't do • How to stay metabolically flexible through perimenopause This episode is for you if: • You're a woman over 35 trying to fast smarter, not harder • You're curious about GLP-1s but want balanced, science-based insight • You've hit a metabolic wall and need smarter strategies • You want practical, hormone-informed tools for fat loss and focus You can also find this episode on… YouTube: https://youtu.be/5oVPHVbyUcw Find more from Cynthia Thurlow: Website: https://www.cynthiathurlow.com Instagram: https://www.instagram.com/cynthia_thurlow_ Find more from Smarter Not Harder: Website: https://troscriptions.com/blogs/podcast?utm_source=youtube&utm_medium=video&utm_campaign=snh_podcast_guest_episode_2025_10&utm_content=podcast_asset Instagram: https://www.instagram.com/troscriptions Get 10% Off your purchase of Clinical Metabolomics Module by using PODCAST10 at https://www.homehope.org Get 10% Off your Troscriptions purchase by using POD10 at https://www.troscriptions.com Get daily content from the hosts of Smarter Not Harder by following @troscriptions on Instagram.

In a newly released email, a US government investigator says that President Donald Trump flew on Jeffrey Epstein's plane many more times than was previously reported. Also: Ukraine says it's suffering widespread power cuts after another night of deadly Russian air attacks; US regulators approve a pill version of the weight loss drug Wegovy; we hear what it's like to have a baby in Bethlehem; and how can you ensure that you'll keep your New Year's resolutions?The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.uk Picture Credit: US Department of Justice/PA

GLP-1 weight-loss drug injections have slimmed many waistlines and wallets. U.S. regulators have now approved a much less expensive alternative; Novo Nordisk has gotten the green light for an oral version of Wegovy. Pills are cheaper to manufacture than injectables, and that could be a game-changer. Then, consumers still feel pessimistic heading into the new year, and more Americans are staying unemployed for longer.

GLP-1 weight-loss drug injections have slimmed many waistlines and wallets. U.S. regulators have now approved a much less expensive alternative; Novo Nordisk has gotten the green light for an oral version of Wegovy. Pills are cheaper to manufacture than injectables, and that could be a game-changer. Then, consumers still feel pessimistic heading into the new year, and more Americans are staying unemployed for longer.

A strike on another suspected drug trafficking boat in the Pacific is again escalating tensions between US and Venezuela. Five people are dead after a plane crash off the coast of Texas. The FDA has approved a pill version of Wegovy. President Donald Trump made his first public comments on the latest release of the Epstein files. Plus, the Kansas City Chiefs are leaving Kansas City, Missouri. Learn more about your ad choices. Visit podcastchoices.com/adchoices

A surprisingly strong GDP report boosted investors' spirits. Plus: American depositary receipts for Novo Nordisk rise after U.S. regulators approved a pill version of weight-loss drug Wegovy. Danny Lewis hosts. Sign up for the WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus: The U.S. bans new China-made drones from DJI and Autel Robotics, sparking outrage among pilots. And U.S. regulators approve the first GLP-1 weight-loss pill, a tablet formulation of Novo Nordisk's Ozempic and Wegovy. Daniel Bach hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla and Jim Cramer led off show with the weight loss drug wars: Shares of Novo Nordisk shares surged after the FDA approved the company's Wegovy pill — making it the first oral GLP-1 cleared by regulators for treatment of obesity. ServiceNow CEO Bill McDermott joined the program to discuss his company's deal to acquire cybersecurity startup Armis for $7.75 billion in cash. Hear what McDermott had to say about this year's slump in shares of ServiceNow and other software stocks. Also in focus: Q3 GDP shows 4.3% growth, the AI trade, countdown to Christmas and new data on holiday spending, Tesla gets a big price target boost on Wall Street, the stock that's getting a lift from President Trump's battleship announcement. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The FDA approving the first GLP-1 pill for obesity from Wegovy maker Novo Nordisk. CNBC speaking with the CEO about expanding access and how the pill will increase the company's competitive edge. Then, former U.K. Treasury Minister Jim O'Neill. His outlook for global markets. And President Trump saying “aggressive housing reform” is coming next year. UBS helps look at possible policy changes and the impact to stocks in the sector. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The latest on severe weather across the country and the impact it's having on the holiday travel rush. Also, the U.S. military announces it has conducted another strike on an alleged drug-smuggling boat. Plus, a homeowner slams into a suspected burglar's car in dramatic video. And, the FDA approves a pill version of the weight-loss injectable drug Wegovy. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The US economy picked up speed over the three months to September, as consumer spending jumped and exports increased but consumer sentiment is low, Rahul Tandon hears from a business about what things are like on the ground. The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according to pharmaceutical giant Novo Nordisk. And, an important moment for Indian female cricket players seeing their match fees doubled for domestic games.(Photo: A person shops for products imported from Asia at a market in Los Angeles, California, USA, 07 April 2025. Credit: ALLISON DINNER/EPA-EFE/REX/Shutterstock)

New figures suggest the US economy is powering ahead but questions remain about what that really means for businesses? Leanna Byrne looks at what's behind the data. Also, US regulators have approved the first pill version of the blockbuster weight-loss drug Wegovy. And could North Koreans be working remotely for US companies?

The Menopause Solution with Dr. Lauren Fitzgerald What was the black box warning? Why was it there? Why is it now gone? (2:09) An interesting symptom of perimenopause. (8:12) Progesterone will change your life! (9:52) The importance of monitoring your thyroid levels and the 10 most common low-thyroid symptoms. (14:20) Testosterone for women. (22:57) Her main issue with primary care doctors. (27:14) The role of peptides in her practice. (30:01) The buy-in. (30:47) Ranking the various applications of testosterone. (33:39) The BIG myths surrounding HRT. (36:03) It's not a business, it's a mission. (40:26) GLP-1s: Incredible tools when used appropriately. (41:40) Normal isn't OPTIMAL. (45:27) The missing element for MOST people. (55:51) Related Links/Products Mentioned Visit Pre-Alcohol by ZBiotics for an exclusive offer for Mind Pump listeners! ** Promo code MINDPUMP25 for 15% off first-time purchasers on either one-time purchases (3, 6, 12-packs) or subscriptions (6, 12-pack) ** MAPS 15 FORTY PLUS 50% half from Dec. 14-20th. Code DECEMBER50 at checkout. Mind Pump Store FDA to Remove 'Black Box' Warnings From Menopause Hormone Therapy. Here's Why. The WHI Study: How Misinterpretation of Hormone Therapy Data Hurt Women's Health Welcome to the 'menodivorce'. Why women aren't sweating marriage in a sea of hot flashes Estrogen Matters: Why Taking Hormones in Menopause Can Improve and Lengthen Women's Lives -- Without Raising the Risk of Breast Cancer Mind Pump #2502: Hormone Therapy for Aesthetics With Dr. Lauren Fitzgerald Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Muscle Mommy Movement Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned LAUREN FITZ, M.D. (@drlaurenfitz) Instagram Website Dr. William Seeds (@williamseedsmd) Instagram Peter Attia, M.D. (@peterattiamd) Instagram

Since Novo Nordisk launched Wegovy in 2021, it has dominated the fast-growing market for slimming drugs. Now a new jab is eating into the Danish firm's success. Why a slang expert thinks the first word humans ever uttered may have been a profane one. And why British sheep have got happier. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.

Since Novo Nordisk launched Wegovy in 2021, it has dominated the fast-growing market for slimming drugs. Now a new jab is eating into the Danish firm's success. Why a slang expert thinks the first word humans ever uttered may have been a profane one. And why British sheep have got happier. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.